摘要
目的探讨应用瑞舒伐他汀治疗急性冠状动脉综合征合并心律失常的患者的作用机制。方法 165例急性冠状动脉综合征患者分为心律失常组与非心律失常组,在常规治疗的基础上均加用瑞舒伐他汀。比较两组治疗前后的一般血液生化指标含量及炎性因子水平。结果治疗前,非心律失常组患者的人高敏C反应蛋白、肿瘤坏死因子-α、白细胞介素-1β、C-myc蛋白水平均低于心律失常组,Bcl-2高于心律失常组,差异有统计学意义(P<0.05)。应用瑞舒伐他汀治疗14 d后,两组患者人高敏C反应蛋白、肿瘤坏死因子-α、白细胞介素-1β、C-myc蛋白水平均显著降低,Bcl-2水平显著升高,差异有统计学意义(P<0.05)。结论瑞舒伐他汀具有一定的调脂、抑制炎性反应作用,且疗效安全,可以用于急性冠脉综合征患者心律失常症状的改善治疗。
Objective To investigate the mechanism of rosuvastatin in patients with acute coronary syndrome compli- cated with arrhythmia. Methods A total of 165 patients with acute coronary artery syndrome were arranged into the ar- rhythmia group and non arrhythmia group. All patients were accepted basis conventional therapy and rosuvastatin. Blood biochemical indexes and inflammatory factor levels of two groups were compared before and after treatment. Re- suits Before treatment, levels of hs-CRP, TNF-α, IL-1β, C-myc protein in non arrhythmia grou were lower than those in arrhythmia group. Bcl-2 were higher than that of arrhythmia group, the difference was statistically significant （P〈 0.05）. After application of rosuvastatin 14 days, levels of hs-CRP, TNF-α, IL-1β, C-myc protein of the two groups were significantly decreased, Bcl-2 levels increased significantly, the difference were statistically significant （P〈0.05）. Conclusion Rosuvastatin has lipid, inhibit inflammatory reaction, and the curative effect is relatively safe, so it can be used to improve symptom of patients with acute coronary syndrome arrhythmia.
出处
《中国现代医生》
2014年第13期71-73,共3页
China Modern Doctor
